Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 81, Issue 2, Pages 259-264Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.clpt.6100055
Keywords
-
Categories
Ask authors/readers for more resources
GARDASIL((R)) (Merck, Whitehouse Station, NJ) is a noninfectious recombinant, quadrivalent vaccine prepared from the highly purified virus-like particles (VLPs) of the major capsid proteins of human papillomavirus (HPV) types 6, 11, 16, and 18. GARDASIL((R)) is the first vaccine approved for use in women aged 9-26 years for the prevention of cervical cancer and genital warts, as well as vulvar and vaginal precancerous lesions. This report describes some of the key preclinical efforts, achievements in pharmaceutical development, in vivo animal evaluation, and clinical trial data.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available